Momenta Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public O...
May 26 2015 - 11:07AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the closing of its underwritten
public offering of 8,337,500 shares of its common stock at the
public offering price of $19.00 per share, which includes the
exercise in full by the underwriters of their option to purchase
1,087,500 additional shares of common stock.
Goldman, Sachs & Co. and J.P. Morgan acted as joint
book-running managers for the offering. Stifel acted as lead
manager.
The offering was made pursuant to an effective shelf
registration statement on Form S-3 that was initially filed with
the U.S. Securities and Exchange Commission (SEC) on April 30,
2013. A final prospectus supplement has been filed with the SEC and
forms a part of the effective registration statement. Copies
of the final prospectus supplement and accompanying prospectus
relating to this offering may be obtained by contacting Goldman,
Sachs & Co., Attention: Prospectus Department, 200 West Street,
New York, New York 10282, or by telephone at (866) 471-2526 or
e-mail at prospectus-ny@ny.email.gs.com or J.P. Morgan Securities
LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717, Phone: (866) 803-9204 or e-mail
at prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
shares of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024